These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21804834)

  • 1. Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010.
    Healthc Policy; 2010 Aug; 6(1):11-4. PubMed ID: 21804834
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization.
    Tadrous M; Knowles S; Ruddock B; Oh P; Mamdani MM; Juurlink DN; Gomes T
    Int J Technol Assess Health Care; 2020; 36(1):12-19. PubMed ID: 31796132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
    Levy AR; Gagnon YM
    Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ontario's formulary committee: how recommendations are made.
    PausJenssen AM; Singer PA; Detsky AS
    Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinician judgement on formulary committees' recommendations in Canada.
    Oremus M; Raina P; Eva K; Lavis J; Nair K; Lo A; Smith S
    J Health Serv Res Policy; 2010 Apr; 15(2):98-105. PubMed ID: 20147424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
    Aspinall SL; Good CB; Glassman PA; Valentino MA
    Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policy and Economic Considerations for Frailty Screening in the Canadian Healthcare System.
    Grimes K; Kitts J; Tholl B; Samuelson-Kiraly C; Mitchell JI
    J Frailty Aging; 2018; 7(4):233-239. PubMed ID: 30298171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of outcomes associated with restricted access to atypical antipsychotics.
    Rajagopalan K; Hassan M; Boswell K; Sarnes E; Meyer K; Grossman F
    Am J Manag Care; 2016 Jun; 22(6):e208-14. PubMed ID: 27355908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing and implementing a statewide formulary system: one state's experience.
    Fiorello SJ
    Formulary; 1995 Dec; 30(12):808-11. PubMed ID: 10153082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan.
    Alabbadi I; Almomani E; Alshazili M
    Value Health Reg Issues; 2020 May; 21():211-221. PubMed ID: 32305828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee's list of recommended essential medicines (the 'Wise List').
    Eriksen J; Ovesjö ML; Vallin M; Juhasz-Haverinen M; Andersén-Karlsson E; Ateva K; Gustafsson LL; Jirlow M; Bastholm-Rahmner P
    Eur J Clin Pharmacol; 2018 Jan; 74(1):131-138. PubMed ID: 29063149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    Cassels A; Law MR
    CMAJ Open; 2019; 7(3):E472-E477. PubMed ID: 31320330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.